Running a clinical trial program in paediatric AML that will gain a PRV is neither easy, quick or cheap. My best estimate is as a standalone program it would take 10 years and cost more than the value of the PRV. The better way of obtaining the PRV is by adding paediatric patients to a primarily adult AML trial, but that requires that you can actually run a sponsored adult AML trial.
The whole PRV becomes a massive distraction when we have opportunities like cardiprotection and m6A. This is where Race should be concentration all its efforts.
RAC - Charts & Price Action, page-18228
-
- There are more pages in this discussion • 3,553 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |